Health
Late-Breaking Data at ACC.21 Show XARELTO® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization – StreetInsider.com
RARITAN, N.J., May 16, 2021 /PRNewswire/ –Â The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD…
RARITAN, N.J., May 16, 2021 /PRNewswire/ – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent…
-
General24 hours agoVictorian school teacher charged with soliciting child abuse material
-
General15 hours agoAustralia loses ODI series to South Africa with defeat in second game in Mackay
-
Noosa News21 hours agoFuel tanker driver killed in horror head-on crash near Blackbutt identified as beloved father-of-two
-
Noosa News19 hours agoPalestine protesters forced into last-minute reroute